2012
DOI: 10.1002/jso.23264
|View full text |Cite
|
Sign up to set email alerts
|

Long intergenic non‐coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder

Abstract: Our data suggest that lincRNA TUG1 is emerging as a novel player in the disease state of bladder urothelial carcinoma. TUG1 may have potential roles as a biomarker and/or a therapeutic target in bladder urothelial carcinoma.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

10
120
0
3

Year Published

2013
2013
2019
2019

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 168 publications
(133 citation statements)
references
References 7 publications
10
120
0
3
Order By: Relevance
“…Our findings were consistent with the data from Han et al [23]. The function of TUG1 was subsequently investigated in our study.…”
Section: Discussionsupporting
confidence: 94%
“…Our findings were consistent with the data from Han et al [23]. The function of TUG1 was subsequently investigated in our study.…”
Section: Discussionsupporting
confidence: 94%
“…Han et al (23) reported that TUG1 is overexpressed in urothelial carcinoma of the bladder and may be a biomarker of bladder urothelial carcinoma and/or a novel target of gene therapy. Zhang et al (24) revealed that downregulating the expression of TUG1 could inhibit osteosarcoma cell proliferation and promote apoptosis, meaning that TUG1 could represent a novel diagnostic marker and a therapeutic target for patients with osteosarcoma.…”
Section: Discussionmentioning
confidence: 99%
“…To date, various profiling strategies have been used to identify differential lncRNA expression in cancer [e.g., analysis of candidate ncRNA (38,39), microarrays (40,41), and transcriptome sequencing (23,42)]. These reports identify that lncRNA expression is often tissue or disease specific (23).…”
Section: Discussionmentioning
confidence: 99%